Access Pharmaceuticals To Host Investor Call On Wednesday, May 23, 2012

_{//health-fitness.news-articles.net/content/2012/ .. host-investor-call-on-wednesday-may-23-2012.html}
^{Published in Health and Fitness on Thursday, May 17th 2012 at 5:57 GMT by Market Wire}  

Access Pharmaceuticals To Host Investor Call On Wednesday, May 23, 2012 -- DALLAS and NEW YORK, May 17, 2012 /PRNewswire/ --

Company Schedules Conference Call Wednesday, May 23rd at 11:00AM ET to Update Investors on MuGard Commercial Activities

DALLAS and NEW YORK, May 17, 2012 /PRNewswire/ -- [ ACCESS PHARMACEUTICALS, INC. ] (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, will host an investor call to update investors on [ MuGard ] commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program.

The investor conference call is scheduled to be held on Wednesday, May 23, 2012 at 11:00 am ET.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. 

A replay of the call will be available starting on May 23, 2012 at 1:00 pm ET, through June 6, 2012 until 11:59 pm ET.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About MuGard:

[ MuGard ] is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of [ oral mucositis ], a debilitating side effect of many anticancer treatments. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit [ www.MuGard.com ].

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include [ MuGard™ ] ([ www.MuGard.com ]), which has received FDA marketing clearance for the management of patients with mucositis, [ ProLindac™, ] a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and [ Thiarabine ]™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including [ CobaCyte™-mediated targeted delivery ] and [ CobOral-oral drug delivery ], its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at [ www.accesspharma.com ].

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.

RELATED LINKS
[ http://www.accesspharma.com ]